Clinical Outcomes with Azelnidipine and Telmisartan Fixed-Dose Combination in Hypertensive Patients: A Real-World, retrospective Study (ACT-HTN Study)

This is a real-world, retrospective, observational study wherein data of patients visiting to various clinics across India will be collected. The objective of this study is to evaluate the tolerability and effectiveness of Azelnidipine/Telmisartan combination as initial-line therapy in treatment-naïve Indian adults with newly diagnosed hypertension.

The Endpoints of the study are as follows -

1. Primary Endpoints:

• Mean change in DBP & SBP from baseline at 12±2 weeks

2. Secondary Endpoints:

• Proportion of patients achieving BP control (defined as mean seated SBP <130 mmHg and DBP <80 mmHg) at 12±2 weeks

• Proportion of patients who sustained or improved on BP control achieved at 12±2 weeks over 24±2 weeks

• Mean change in Heart Rate from baseline at 12±2 weeks

• Incidence of adverse events

Data for approximately 4,000 patients from different sites across India will be collected for the purpose of this study.

The available data must meet all the following criteria to be included in the study:

1. Inclusion Criteria

• Adult Male or female patients with newly diagnosed hypertension (BP >140/90 mmHg)

• Patients diagnosed with hypertension and treated with Azelnidipine/telmisartan combination as initial line therapy

2. Exclusion Criteria

• Patients with current or past exposure to antihypertensive medications other than study drug

Descriptive statistical analysis will be performed on all collected data and reports will be generated.